Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15893908rdf:typepubmed:Citationlld:pubmed
pubmed-article:15893908lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:15893908lifeskim:mentionsumls-concept:C0031268lld:lifeskim
pubmed-article:15893908lifeskim:mentionsumls-concept:C0278689lld:lifeskim
pubmed-article:15893908lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:15893908lifeskim:mentionsumls-concept:C0032743lld:lifeskim
pubmed-article:15893908lifeskim:mentionsumls-concept:C0033522lld:lifeskim
pubmed-article:15893908pubmed:issue7lld:pubmed
pubmed-article:15893908pubmed:dateCreated2005-8-29lld:pubmed
pubmed-article:15893908pubmed:abstractTextMany patients with ovarian cancer are at high risk of recurrence especially in the 2 years following first-line therapy. CA125 serum levels measurement associated to computed tomography (CT), ultrasound (US) and magnetic resonance imaging (MRI) are currently used during follow-up to detect recurrent disease. Unfortunately, in a relevant percentage of cases all of these traditional imaging techniques provide a significant number of doubtful/equivocal results or turn out negative even in presence of elevated Ca125 levels. Aim of our study was to evaluate sensitivity, specificity and accuracy of (18)F-FDG PET/CT in a group of patients with suspicion of ovarian cancer recurrence.lld:pubmed
pubmed-article:15893908pubmed:languageenglld:pubmed
pubmed-article:15893908pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15893908pubmed:citationSubsetIMlld:pubmed
pubmed-article:15893908pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15893908pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15893908pubmed:statusMEDLINElld:pubmed
pubmed-article:15893908pubmed:monthSeplld:pubmed
pubmed-article:15893908pubmed:issn0748-7983lld:pubmed
pubmed-article:15893908pubmed:authorpubmed-author:ChewH CHClld:pubmed
pubmed-article:15893908pubmed:authorpubmed-author:MarianiGGlld:pubmed
pubmed-article:15893908pubmed:authorpubmed-author:RubelloDDlld:pubmed
pubmed-article:15893908pubmed:authorpubmed-author:FantlPPlld:pubmed
pubmed-article:15893908pubmed:authorpubmed-author:NanniCClld:pubmed
pubmed-article:15893908pubmed:authorpubmed-author:De IacoPPlld:pubmed
pubmed-article:15893908pubmed:authorpubmed-author:RampinLLlld:pubmed
pubmed-article:15893908pubmed:authorpubmed-author:FarsadMMlld:pubmed
pubmed-article:15893908pubmed:authorpubmed-author:SansoviniMMlld:pubmed
pubmed-article:15893908pubmed:issnTypePrintlld:pubmed
pubmed-article:15893908pubmed:volume31lld:pubmed
pubmed-article:15893908pubmed:ownerNLMlld:pubmed
pubmed-article:15893908pubmed:authorsCompleteYlld:pubmed
pubmed-article:15893908pubmed:pagination792-7lld:pubmed
pubmed-article:15893908pubmed:dateRevised2007-7-2lld:pubmed
pubmed-article:15893908pubmed:meshHeadingpubmed-meshheading:15893908...lld:pubmed
pubmed-article:15893908pubmed:meshHeadingpubmed-meshheading:15893908...lld:pubmed
pubmed-article:15893908pubmed:meshHeadingpubmed-meshheading:15893908...lld:pubmed
pubmed-article:15893908pubmed:meshHeadingpubmed-meshheading:15893908...lld:pubmed
pubmed-article:15893908pubmed:meshHeadingpubmed-meshheading:15893908...lld:pubmed
pubmed-article:15893908pubmed:meshHeadingpubmed-meshheading:15893908...lld:pubmed
pubmed-article:15893908pubmed:meshHeadingpubmed-meshheading:15893908...lld:pubmed
pubmed-article:15893908pubmed:meshHeadingpubmed-meshheading:15893908...lld:pubmed
pubmed-article:15893908pubmed:meshHeadingpubmed-meshheading:15893908...lld:pubmed
pubmed-article:15893908pubmed:meshHeadingpubmed-meshheading:15893908...lld:pubmed
pubmed-article:15893908pubmed:meshHeadingpubmed-meshheading:15893908...lld:pubmed
pubmed-article:15893908pubmed:meshHeadingpubmed-meshheading:15893908...lld:pubmed
pubmed-article:15893908pubmed:meshHeadingpubmed-meshheading:15893908...lld:pubmed
pubmed-article:15893908pubmed:meshHeadingpubmed-meshheading:15893908...lld:pubmed
pubmed-article:15893908pubmed:meshHeadingpubmed-meshheading:15893908...lld:pubmed
pubmed-article:15893908pubmed:year2005lld:pubmed
pubmed-article:15893908pubmed:articleTitle(18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients.lld:pubmed
pubmed-article:15893908pubmed:affiliationNuclear Medicine Department, S. Orsola-Malpighi Hospital, Bologna, Italy.lld:pubmed
pubmed-article:15893908pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15893908pubmed:publicationTypeClinical Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15893908lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15893908lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15893908lld:pubmed